

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8031135

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
CADENCE BANK, A MISSISSIPPI BANK AND SUCCESSOR BY MERGER TO CADENCE BANK, N.A., A NATIONAL BANKING ASSOCIATION, AS AGENT	06/28/2023

**RECEIVING PARTY DATA**

<b>Name:</b>	ENTERIS BIOPHARMA, INC.
<b>Street Address:</b>	5956 SHERRY LANE, SUITE 650
<b>City:</b>	DALLAS
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75225

**PROPERTY NUMBERS Total: 53**

Property Type	Number
Application Number:	60940598
Patent Number:	8377863
Patent Number:	8513183
Patent Number:	8664178
Patent Number:	8592366
Patent Number:	9399017
PCT Number:	US0806804
Application Number:	60748954
Patent Number:	8093207
PCT Number:	US0647108
Application Number:	60441856
PCT Number:	US0401633
Patent Number:	8088734
Application Number:	60250055
Patent Number:	6673574
PCT Number:	US0144980
Application Number:	60274317
Patent Number:	7316819
PCT Number:	US0207197
Application Number:	60552824

PATENT

Property Type	Number
Patent Number:	8227241
Patent Number:	8216822
Patent Number:	8835161
PCT Number:	US0507873
Application Number:	60630748
Patent Number:	7445911
Patent Number:	8163871
PCT Number:	US0542765
Application Number:	60693612
Patent Number:	8815583
PCT Number:	US0624687
Application Number:	60580872
Patent Number:	8835377
Patent Number:	9504727
Application Number:	60180241
Application Number:	10774358
Application Number:	12459385
PCT Number:	US0103212
Patent Number:	8252580
Patent Number:	7553655
Application Number:	62371377
PCT Number:	US1745229
Application Number:	16267902
Application Number:	61772927
Application Number:	61925443
Patent Number:	9457086
PCT Number:	US1420763
Patent Number:	9526785
Patent Number:	9744140
Application Number:	62102263
Patent Number:	9833411
PCT Number:	US1612970
Application Number:	15802754

#### CORRESPONDENCE DATA

Fax Number: (404)522-8409

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 4044205527

**Email:** rjk@phrd.com  
**Correspondent Name:** RHONDA J. KENYERI, PARALEGAL  
**Address Line 1:** 303 PEACHTREE STREET, SUITE 3600  
**Address Line 4:** ATLANTA, GEORGIA 30308

<b>NAME OF SUBMITTER:</b>	KATHLEEN O. CURREY
---------------------------	--------------------

<b>SIGNATURE:</b>	/koc/
-------------------	-------

<b>DATE SIGNED:</b>	06/28/2023
---------------------	------------

**Total Attachments: 13**

source=03. Release of Security Interest in Patents (SWK Holdings)#page1.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page2.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page3.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page4.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page5.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page6.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page7.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page8.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page9.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page10.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page11.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page12.tif  
source=03. Release of Security Interest in Patents (SWK Holdings)#page13.tif

**RELEASE OF SECURITY INTEREST IN PATENTS**

June 28, 2023

FOR VALUE RECEIVED, the undersigned, **CADENCE BANK**, a Mississippi bank and successor by merger to Cadence Bank, N.A., a national banking association, as agent for various financial institutions (together with its successors and assigns, "Agent"), does hereby release, relinquish, terminate and cancel any and all liens and security interests granted to Agent by the Company (as defined below), in and to the patents listed on Schedule A attached hereto (collectively, the "Patent Collateral"), arising under that certain Patent Security Agreement dated August 26, 2019, by and between **ENTERIS BIOPHARMA, INC.**, a Delaware corporation (the "Company"), and Agent, recorded with the United States Patent and Trademark Office on August 26, 2019, at Reel 050174, Frame 0428 (the "Patent Agreement"). This Release of Security Interest in Patent (this "Release") may be filed with the United States Patent and Trademark Office to evidence Agent's release of the security interest against such patents.

This Release is intended to operate as a release of all liens and security interests in the patents listed on Schedule A attached hereto, conveyed by the Company to Agent pursuant to the terms of the Patent Agreement, without any representation, warranty or undertaking by, or recourse to, Agent. If and to the extent Agent has acquired any right, title or interest in and to any of the Patent Collateral pursuant to the terms of the Patent Agreement, Agent hereby reassigns and transfers such right, title and interest to the Company, together with the goodwill of the Company's business connected with and symbolized by the Patent Collateral, without any representation, warranty or undertaking by, or recourse to, Agent.

[Remainder of page intentionally left blank; signature appears on the following page.]

IN WITNESS WHEREOF, Agent has caused this Release to be signed and sealed by its duly authorized officer as of the date first written above.

CADENCE BANK, successor by merger to  
Cadence Bank, N.A., as Agent

By: Kenneth B. Butler  
Name: Kenneth B. Butler  
Title: Senior Vice President

## SCHEDULE A

### Patents and Patent Applications

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
Peptide Pharmaceutical for Oral Delivery	146551-546418	US PROV	60/940,598 filed 5/29/07
	146551-546457	US	12/128,210 filed 5/28/08 8,377,863 issued 2/19/13
	146551-464571	US	13/283,055 filed 10/27/11 8,513,183 issued 8/20/13
	146551-464572	US	13/487,784 filed 6/4/12 8,664,178 issued 3/4/14
	146551-464573	US	13/487,856 filed 6/4/12 8,592,366 issued 11/6/13
	146551-464574	US	14/158,029 filed 1/17/14 9,399,017 issued 7/26/16
	146551-546458	PCT	PCT/US08/06804 filed 5/29/08 WO/2008/150426 published 12/11/08
	146551-546498	AUSTRALIA	2008260615 issued 1/19/12
	146551-546499	CANADA	2,689,358 issued 11/27/12
	146551-546500	CHINA	ZL 200880018288.8 issued 5/8/13
	146551-546501	EUROPE	2,152,195 issued 11/11/15
	146551-465011	BELGIUM	2,152,195 issued 11/11/15
	146551-465012	DENMARK	2,152,195 issued 11/11/15
	146551-465013	FRANCE	2,152,195 issued 11/11/15

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
	146551-465014	GERMANY	2,152,195 issued 11/11/15
	146551-465015	ITALY	2,152,195 issued 11/11/15
	146551-465016	NETHERLANDS	2,152,195 issued 11/11/15
	146551-465017	PORTUGAL	2,152,195 issued 11/11/15
	146551-465018	SPAIN	2,152,195 issued 11/11/15
	146551-465019	SWEDEN	2,152,195 issued 11/11/15
	146551-465020	SWITZERLAND	2,152,195 issued 11/11/15
	146551-465021	UNITED KINGDOM	2,152,195 issued 11/11/15
	146551-546503	EUROPE DIV	3009129 issued 8/9/17
	146551-465031	FRANCE	2008260615 issued 8/9/17
	146551-465032	GERMANY	602008051598.2. issued 8/9/17
	146551-465033	GREAT BRITAIN	3009129 issued 8/9/17
	146551-546502	JAPAN	5365629 issued 9/20/13
Fast-Acting Oral Peptide Pharmaceutical Products	146551-546331	US PROV	60/748,954 filed 12/9/05
	146551-546396	US	11/567,454 filed 12/6/06 8,093,207 issued 1/10/12
	146551-546397	PCT	PCT/US06/47108 filed 12/8/06 WO/07/070450 published 6/21/07
	146551-546459	AUSTRALIA	2006326580 issued 2/14/10
	146551-546460	CANADA	2,631,841 issued 5/8/12
	146551-546461	CHINA	ZL 2006 8 0046022.5 issued 4/18/12
	146551-546462	EUROPE	1957054 issued 4/8/15
	146551-464621	DENMARK	1957054 issued 4/8/15
	146551-464622	FRANCE	1957054 issued 4/8/15

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
	146551-464623	GERMANY	1957054 issued 4/8/15
	146551-464624	SWEDEN	1957054 issued 4/8/15
	146551-464625	SWITZERLAND	1957054 issued 4/8/15
	146551-464626	SPAIN	1957054 issued 4/8/15
	146551-464627	UNITED KINGDOM	1957054 issued 4/8/15
Oral Delivery of Peptides	146551-546251	US PROV	60/441,856 filed 1/21/03
	146551-546282	PCT	PCT/US04/01633 filed 1/21/04 WO/04/064758 published 8/5/04
	146551-546280	US	10/761,481 filed 1/20/04 8,088,734 issued 1/3/12
	146551-546343	AUSTRALIA	2004206949 issued 11/12/09
	146551-546341	CANADA	2,512,824 issued 7/9/13
	146551-546344	CHINA	ZL 200480002372 issued 7/8/09
	146551-546342	EUROPE	04704114.0 1585503 issued 1/20/16
	146551-463421	DENMARK	1585503 issued 1/20/16
	146551-463422	FRANCE	1585503 issued 1/20/16
	146551-463423	GERMANY	1585503 issued 1/20/16
	146551-463424	SPAIN	1585503 issued 1/20/16
	146551-463425	SWEDEN	1585503 issued 1/20/16
	146551-463426	SWITZERLAND	1585503 issued 1/20/16
	146551-463427	UNITED KINGDOM	1585503 issued 1/20/16



TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
Oral Delivery Of Peptides Using Enzyme-Cleavable Membrane Translocators	146551-546222	US PROV	60/250,055 filed 11/30/00
	146551-546247	US	09/997,465 filed 11/29/01 6,673,574 issued 1/6/04
	146551-546248	PCT	PCT/US01/44980 filed 11/30/01 WO/2002/043767 published 6/6/02
	146551-546266	AUSTRALIA	2002227060 issued 8/30/07
	146551-546264	CANADA	2,430,366 issued 9/28/10
	146551-546265	EUROPE	1339431 issued 6/28/17
	146551-462651	DENMARK	1339431 issued 6/28/17
	146551-462652	FRANCE	1339431 issued 6/28/17
	146551-462653	GERMANY	601 50 506.9 issued 6/28/17
	146551-462654	SPAIN	2642628 issued 6/28/17
	146551-462655	SWEDEN	1339431 issued 6/28/17
	146551-462656	SWITZERLAND	1339431 issued 6/28/17
	146551-462657	UNITED KINGDOM	1339431 issued 6/28/17
	146551-546267	JAPAN	4476544 issued 3/19/10
Oral Peptide Pharmaceutical Dosage Form And Method Of Production	146551-546250	US PROV	60/274,317 filed 3/8/01
	146551-546255	US	10/094,306 filed 3/7/02 7,316,819 issued 1/8/08
	146551-546256	PCT	PCT/US02/07197

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
			filed 3/8/02 WO/02/072075 published 9/19/02
	146551-546271	CANADA	2,440,578 issued 5/26/09
	146551-546276	NEW ZEALAND	527844 issued 12/8/05
Bacterial Host Cell for the Direct Expression of Peptides	146551-546270	US PROV	60/552,824 filed 3/12/13
	146551-546325	US	11/076,260 filed 3/9/05 8,227,241 issued 7/24/12
	146551-546382	US	11/928,936 filed 10/30/07 8,216,822 issued 7/10/12
	146551-463821	US	13/544,228 filed 7/9/12 8,835,161 issued 9/16/14
	146551-546326	PCT	PCT/US05/07873 filed 3/10/05 WO/05/089182 published 9/29/05
	146551-546373	CANADA	2557295 issued 1/29/13
	146551-463731	CANADA	2795418 issued 2/24/15
	146551-546374	CHINA	ZL 200580007801.X issued 7/4/12
	146551-546521	CHINA	ZL 201110107199.4 issued 12/3/14
	146551-546375	EUROPE	1733039 issued 9/25/13
	146551-463751	SWITZERLAND	1733039 issued 9/25/13
	146551-463752	GERMANY	1733039 issued 9/25/13
	146551-463753	DENMARK	1733039 issued 9/25/13

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
	146551-463754	SPAIN	1733039 issued 9/25/13
	146551-463755	FRANCE	1733039 issued 9/25/13
	146551-463756	UK	1733039 issued 9/25/13
	146551-463757	SWEDEN	1733039 issued 9/25/13
	146551-546479	EUROPE	2067854 issued 11/5/14
	146551-464791	SWITZERLAND	2067854 issued 11/5/14
	146551-464792	GERMANY	2067854 issued 11/5/14
	146551-464793	DENMARK	2067854 issued 11/5/14
	146551-464794	SPAIN	2067854 issued 11/5/14
	146551-464795	FRANCE	2067854 issued 11/5/14
	146551-464796	UK	2067854 issued 11/5/14
	146551-464797	SWEDEN	2067854 issued 11/5/14
	146551-546376	JAPAN	5591447 issued 8/8/14

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
Enzymatic Reactions in the Presence of Keto Acids	146551-546291	US PROV	60/630,748 filed 11/24/04
	146551-546355	US	11/285,136 filed 11/22/05 7,445,911 issued 11/4/08
	146551-546476	US	12/284,552 filed 9/22/08 8,163,871 issued 4/24/12
	146551-546356	PCT	PCT/US05/42765 filed 11/23/05 WO/2006/058225 published 6/1/06
	146551-546410	AUSTRALIA	2005309479 issued 9/23/10
	146551-546411	CANADA	2,568,128 issued 4/2/13
	146551-546412	CHINA	ZL200580040163.1 issued 11/16/11
	146551-546414	JAPAN	4891256 issued 12/22/11
Cell Lines for Expressing Enzyme Useful in the Preparation of Amidated Products	146551-546268	US PROV	60/693,612 filed 6/24/05
	146551-546367	US	11/474,159 filed 6/23/06 8,815,583 issued 8/26/14
	146551-546368	PCT	PCT/US06/24687 filed 6/23/06 WO/2007/002532 published 1/4/07
	146551-546442	AUSTRALIA	2006261909 issued 11/24/11
	146551-546443	CANADA	2,613,471 issued 9/6/16
	146551-546444	CHINA	ZL200680030902.3 issued 4/10/13
	146551-546445	JAPAN	4856177 issued 11/4/11
	146551-546544	JAPAN	5568703 issued 7/4/14

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
	146551-464451	JAPAN	5677918 issued 1/9/15
	146551-546446	EUROPE	1907561 issued 8/28/13
	146551-464461	SWITZERLAND	1907561 issued 8/28/13
	146551-464462	GERMANY	1907561 issued 8/28/13
	146551-464463	DENMARK	1907561 issued 8/28/13
	146551-464464	SPAIN	1907561 issued 8/28/13
	146551-464465	FRANCE	1907561 issued 8/28/13
	146551-464466	UK	1907561 issued 8/28/13
	146551-464467	SWEDEN	1907561 issued 8/28/13
Oral Delivery of Peptide Pharmaceutical Compositions	146551-546290	US PROV	60/580,872 filed 6/18/04
	146551-463271	US	13/219,132 filed 8/26/11 8,835,377 issued 9/16/14
	146551-463272	US	14/484,745 filed 9/12/14 9,504,727 issued 11/29/16

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
Nasal Calcitonin Formulation	146551-546212	US PROV	60/180,241 filed 2/4/00
	146551-546279	US	10/774,358 filed 2/5/04 RE40,812 issued 6/30/09
	146551-546477	US	12/459,385 filed 6/29/09 RE43,580 issued 8/14/12
	146551-546235	PCT	PCT/US01/03212 filed 1/31/01 WO/2001/056594 published 8/9/01
	146551-546258	CANADA	2,399,505 issued 1/3/12
	146551-546260	AUSTRALIA	783952 issued 4/27/06
	146551-546435	CHINA	ZL01807605.X issued 1/12/05
Bacterial Host Cell for the Direct Expression of Peptides	146551-546383	US	11/928,994 filed 10/30/07 8,252,580 issued 8/28/12
	146551-546385	US	11/929,079 filed 10/30/07 7,553,655 issued 6/30/09
Room Temperature Stable Oral Calcitonin Formulation	146551-010103	US PROV	62/371,377 filed 8/5/16
	146551-010104	PCT	PCT/US17/45229 filed 8/3/17 WO/2018/026993 published 2/8/18
	146551-010105	US	16/267,902 filed 02/05/19 US 2019/0192442 published 6/27/19
	146551-010106	AUSTRALIA	2017305415 filed 8/3/17
	146551-010107	BRAZIL	BR112019002031-4 filed 8/3/17
	146551-010108	CANADA	3,032,823 filed 8/3/17
	146551-010109	CHINA	201780057229.0 filed 8/3/17

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
	146551-010110	JAPAN	2019-527773 filed 8/3/17
	146551-010111	KOREA	10-2019-7006378 filed 8/3/17
	146551-010112	MEXICO	MX/a/2019/001399 filed 8/3/17
	146551-010113	RUSSIA	2019105756 filed 8/3/17
Pharmaceuticals for Oral Delivery	146551-010500	US PROV	61/772,927 filed 3/5/13
	146551-010501	US PROV	61/925,443 filed 1/9/14
	146551-010502	US	14/197,405 filed 3/5/14 9,457,086 issued 10/4/16
	146551-010503	PCT	PCT/US14/20763 filed 3/5/14 WO/2014/138241 published 9/12/14
	146551-010504	AUSTRALIA	2014225822 filed 3/5/14 2014225822 issued 8/17/17
	146551-010505	CANADA	2,904,327 filed 3/5/14
	146551-010506	CHINA	201480020438.4 filed 3/5/14 CN 105101950 A published 11/25/15
	146551-010507	EUROPE	14714013.1 filed 3/5/14 2964193 published 1/13/16
	146551-010508	ISRAEL	240,666 filed 3/5/14
	146551-010509	JAPAN	2015-561608 filed 3/5/14 6375314 issued 7/27/18
	146551-010510	HONG KONG	16104122.5 filed 3/5/14 HK 1216082 published 10/14/16
	146551-010511	US CON	15/184,971 filed 6/16/16 9,526,785 issued

TITLE	FILE #	COUNTRY	APPLICATION/ PATENT NO.
			12/27/16
	146551-010512	US CON2	15/353,213 filed 11/16/16 9,744,140 issued 8/29/17
	146551-010513	AUSTRALIA	2017202900 filed 3/5/14 2017202900 issued 8/9/18
	146551-010515	AUSTRALIA	2018206721 filed 3/5/14
Solid Oral Dosage Forms	146551-010900	US PROV	62/102,263 filed 1/12/15
	146551-010901	US	14/993,294 filed 1/12/16 9,833,411 issued 12/5/17
	146551-010902	PCT	PCT/US16/12970 filed 1/12/16 WO/2016/115082 published 7/21/16
	146551-010903	AUSTRALIA	2016206950 filed 1/12/16
	146551-010904	CANADA	2,973,099 filed 1/12/16
	146551-010905	CHINA	201680012731.5 filed 1/12/16 CN 107427469 published 12/1/17
	146551-010906	EUROPE	16708750.1 filed 1/12/16 3244878 published 11/22/17
	146551-010907	JAPAN	2017-536831 filed 1/12/16
	146551-010908	KOREA	10-2017-7022584 filed 1/12/16
	146551-010909	US CON	15/802,754 filed 11/3/17 US 2018/0049987 published 2/22/18